Literature DB >> 2233746

Expression of human 21-hydroxylase (P450c21) in bacterial and mammalian cells: a system to characterize normal and mutant enzymes.

M C Hu1, B C Chung.   

Abstract

Cytochrome P450c21 (steroid 21-hydroxylase) is a key enzyme in the synthesis of cortisol, whose deficiency is the cause of a common genetic disease, congenital adrenal hyperplasia. We have expressed P450c21 (steroid 21-hydroxylase) in E. coli and mammalian cells. In E. coli, P450c21 cDNA was cloned into a T7 expression vector to produce a large amount of P450c21 fusion protein, which enabled antiserum production. In mammalian cells, a plasmid containing full-length P450c21 cDNA (phc21) was constructed and transfected into COS-1 cells to produce active P450c21, which was detected by immunoblotting and 21-hydroxylase activity assay. This system was used to assay mutations involved in the disease. Ile172 of phc21 corresponding to the site of mutation in some cases of the disease was mutagenized to become Asn, Leu, His, or Gln. Mutant as well as normal P450c21 was produced when their cDNAs were transfected into COS-1 cells. The mutant proteins, however, had greatly reduced 21-hydroxylase activities. Therefore, missense mutation at Ile172 resulted in inactivation of the enzyme, but not in repression of enzyme synthesis. The Leu for Ile substitution at amino acid 172 did not result in partial restoration of enzymatic activity, indicating that hydrophobicity at this residue may not play a role in its function.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2233746     DOI: 10.1210/mend-4-6-893

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  9 in total

1.  Function and membrane topology of wild-type and mutated cytochrome P-450c21.

Authors:  M C Hu; L C Hsu; N C Hsu; B C Chung
Journal:  Biochem J       Date:  1996-05-15       Impact factor: 3.857

Review 2.  The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders.

Authors:  Walter L Miller; Richard J Auchus
Journal:  Endocr Rev       Date:  2010-11-04       Impact factor: 19.871

3.  SF-1 (nuclear receptor 5A1) activity is activated by cyclic AMP via p300-mediated recruitment to active foci, acetylation, and increased DNA binding.

Authors:  Wei-Yi Chen; Li-Jung Juan; Bon-Chu Chung
Journal:  Mol Cell Biol       Date:  2005-12       Impact factor: 4.272

4.  Analysis of In Vivo Activity of the Bovine Cholesterol Hydroxylase/Lyase System Proteins Expressed in Escherichia coli.

Authors:  V S Efimova; L V Isaeva; M A Rubtsov; L A Novikova
Journal:  Mol Biotechnol       Date:  2019-04       Impact factor: 2.695

5.  In humans, early cortisol biosynthesis provides a mechanism to safeguard female sexual development.

Authors:  Masahiro Goto; Karen Piper Hanley; Josep Marcos; Peter J Wood; Sarah Wright; Anthony D Postle; Iain T Cameron; J Ian Mason; David I Wilson; Neil A Hanley
Journal:  J Clin Invest       Date:  2006-04       Impact factor: 14.808

6.  Mutations of P450c21 (steroid 21-hydroxylase) at Cys428, Val281, and Ser268 result in complete, partial, or no loss of enzymatic activity, respectively.

Authors:  D A Wu; B C Chung
Journal:  J Clin Invest       Date:  1991-08       Impact factor: 14.808

7.  Histone deacetylase inhibitors reduce steroidogenesis through SCF-mediated ubiquitination and degradation of steroidogenic factor 1 (NR5A1).

Authors:  Wei-Yi Chen; Jui-Hsia Weng; Chen-Che Huang; Bon-Chu Chung
Journal:  Mol Cell Biol       Date:  2007-08-20       Impact factor: 4.272

Review 8.  Congenital Adrenal Hyperplasia-Current Insights in Pathophysiology, Diagnostics, and Management.

Authors:  Hedi L Claahsen-van der Grinten; Phyllis W Speiser; S Faisal Ahmed; Wiebke Arlt; Richard J Auchus; Henrik Falhammar; Christa E Flück; Leonardo Guasti; Angela Huebner; Barbara B M Kortmann; Nils Krone; Deborah P Merke; Walter L Miller; Anna Nordenström; Nicole Reisch; David E Sandberg; Nike M M L Stikkelbroeck; Philippe Touraine; Agustini Utari; Stefan A Wudy; Perrin C White
Journal:  Endocr Rev       Date:  2022-01-12       Impact factor: 19.871

Review 9.  Management challenges and therapeutic advances in congenital adrenal hyperplasia.

Authors:  Ashwini Mallappa; Deborah P Merke
Journal:  Nat Rev Endocrinol       Date:  2022-04-11       Impact factor: 47.564

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.